Please login to the form below

Not currently logged in
Email:
Password:

Caldan Therapeutics appoints CEO

Dr Mark Payton joins the Universities of Glasgow and Southern Denmark spin-out

Caldan Therapeutics Dr Mark PaytonEdinburgh, UK-based Caldan Therapeutics has appointed Dr Mark Payton as chief executive officer.

Dr Payton joins the metabolic disease specialist - a spin-out company from the Universities of Glasgow and Southern Denmark - from MAPBiotech, where he has served as chief executive officer since 2014.

Prior to this, Dr Payton has been chief executive officer of both Atopix Therapeutics and Oxagen, both based in Oxfordshire, UK, and brings further industry experience from GlaxoSmithKline and Biogen.

He co-founded autoimmune disease-focused Orca Pharmaceuticals in 2012, and currently also serves as a senior advisor to The Harrington Project for Discovery and Development.

Dr Liz Roper, partner at Epidarex Capital, which backs Caldan Therapeutics, said: “We are delighted to welcome Mark on board to lead Caldan Therapeutics moving forward.

“Continuing to build a strong management team with experienced and talented executives is crucial to building on the science of Professors Milligan and Ulven to deliver new drugs for metabolic diseases.”

8th March 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics